Graft-versus-host-disease Clinical Trial
Official title:
Letermovir Prophylaxis for CMV in Patients With Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation: a Proof of Concept Multicenter Study
Explore the tolerability and efficacy of letermovir in the prevention of CMV reactivation in patients with acute and chronic graft-versus-host disease (GVHD) beyond day 100.
42 patients meeting the inclusion criteria will receive letermovir 480 mg per day. Patients receiving concomitant cyclosporine will receive 240 mg of letermovir. Letermovir will be given during 14 weeks or until prednisone dose is reduced below 0.2 mg / kg / day, whichever comes earlier. All the patients will continue herpesvirus prophylaxis with acyclovir or valacyclovir. Patients will be evaluated biweekly until letermovir discontinuation. A PCR CMV test will be performed biweekly. Patients in whom clinically significant CMV infection (defined as CMV disease or CMV viremia leading to preemptive treatment) develop, will discontinue the trial regimen and begin anti-CMV therapy according to local practice. The threshold for preemptive treatment for CMV viremia will be >1000 copies/ ml. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04792580 -
The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease
|
Early Phase 1 | |
| Active, not recruiting |
NCT04669210 -
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
|
Phase 2 | |
| Completed |
NCT04014790 -
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT06008808 -
Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT03395860 -
Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT
|
Phase 2 | |
| Completed |
NCT03207958 -
Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
|
Phase 1 | |
| Completed |
NCT03414645 -
Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT03846479 -
Itacitinib for Low Risk GVHD
|
Phase 2 | |
| Active, not recruiting |
NCT01927120 -
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis
|
Phase 2 | |
| Recruiting |
NCT06321003 -
SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
|
||
| Not yet recruiting |
NCT06279585 -
Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD
|
N/A | |
| Suspended |
NCT05617625 -
CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome
|
Phase 2 | |
| Not yet recruiting |
NCT06392711 -
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
|
Phase 1 | |
| Withdrawn |
NCT00723593 -
Natural History and Pathophysiology of Gastrointestinal Graft-versus-Host Disease
|
N/A | |
| Recruiting |
NCT03148197 -
Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT)
|
N/A | |
| Recruiting |
NCT03456817 -
HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis
|
Phase 2 | |
| Completed |
NCT00827398 -
Treatment of Steroid Resistant GVHD by Infusion MSC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03842696 -
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT03605927 -
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
|
Phase 1 | |
| Recruiting |
NCT04688021 -
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
|
Phase 2 |